Sarah Cappuyns

Du Cane Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal: Journal of hepatology

Published: September 04, 2025

Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment.

Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment.

Journal: Cell reports. Medicine

Published: September 27, 2024

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma.

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma.

Journal: Cancer discovery

Published: August 22, 2024

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.

Journal: JHEP reports : innovation in hepatology

Published: April 05, 2024

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Journal: Journal of hepatology

Published: February 02, 2024

Applications of single-cell multi-omics in liver cancer.

Applications of single-cell multi-omics in liver cancer.

Journal: JHEP reports : innovation in hepatology

Published: January 31, 2024

HIMALAYA Overall Survival Prominence and Other Routes to the Peak-Reply.

HIMALAYA Overall Survival Prominence and Other Routes to the Peak-Reply.

Journal: JAMA oncology

Published: January 11, 2024

Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.

Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.

Journal: BJC reports

Published: October 05, 2023

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.

Journal: JAMA oncology

Published: August 03, 2023

Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study.

Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study.

Journal: Clinical colorectal cancer

Published: May 04, 2023

PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Journal: Nature communications

Published: April 19, 2023

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma.

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma.

Journal: Cancers

Published: October 24, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026